Stephen Wu
Subscribe to Stephen Wu's PostsStephen Wu focuses his practice on antitrust litigation, defending mergers and acquisitions before antitrust enforcement agencies and counseling clients on antitrust compliance issues. He represents clients in a wide variety of industries ranging from aerospace to consumer products and food, with a particular concentration on health care antitrust matters. He is co-chair of the Firm’s Health Antitrust Affinity Group. Read Stephen Wu's full bio.
DOJ Signals Heightened Scrutiny on Information Exchanges and Competitor Collaborations
By Noah Feldman Greene, Gregory E. Heltzer, Ashley Fischer and Stephen Wu on Feb 15, 2023
Posted In DOJ Developments, Healthcare Antitrust
WHAT HAPPENED On February 3, 2023, the US Department of Justice’s (DOJ) Antitrust Division announced the withdrawal of three policy statements related to antitrust enforcement in healthcare. Although the withdrawn statements focus on healthcare, DOJ’s decision to withdraw these statements will have broad impacts across industries. The three policy statements, issued in 1993, 1996, and 2011, relate to competitor collaboration...
Continue Reading
Recent Treasury Department Report Emphasizes Fostering Competition in Labor Markets
By Joshua W. Eastby and Stephen Wu on Mar 15, 2022
Posted In Agriculture, Cartel Enforcement, DOJ Developments, Healthcare Antitrust, Joint Ventures/Competitor Collaboration, Monopolization/Abuse of Dominance
Continuing the recent string of actions across the Biden administration in response to the July 2021 Executive Order on “Promoting Competition in the American Economy,” on March 7, 2022, the US Treasury Department (Treasury) released a report titled “The State of Labor Market Competition,” and on March 10, 2022, the US Departments of Justice (DOJ)...
Continue Reading
2020 Health Antitrust Year in Review
By Ashley Fischer, Katharine M. O'Connor, Stephen Wu and Michelle Lowery on Jan 19, 2021
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Joint Ventures/Competitor Collaboration, Mergers & Acquisitions, Monopolization/Abuse of Dominance, Private Litigation
The federal antitrust enforcement agencies brought three hospital merger challenges and three criminal antitrust enforcement actions in healthcare in the past year. Combined with the incoming Democratic administration, healthcare antitrust enforcement is likely to remain strong in 2021. Our Health Antitrust Year in Review: Examines specific antitrust challenges and enforcement actions that impacted hospitals and...
Continue Reading
Health Antitrust Litigation Update for Providers | 2020
By Michelle Lowery, Katharine M. O'Connor, Stephen Wu, Joshua W. Eastby and Ashley Fischer on Nov 13, 2020
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Joint Ventures/Competitor Collaboration, Mergers & Acquisitions, Monopolization/Abuse of Dominance, Private Litigation
In 2019, the total number of antitrust cases filed against providers dropped to 20 after the 2018 bump (27 cases). In the latest Health Antitrust Litigation Update for Providers, we discuss what kinds of cases were brought over the past two years and how they were decided, and what cases warrant particular attention in 2020. Read...
Continue Reading
Top Takeaways: Permissible Provider Collaborations During COVID-19 and Beyond
By Ashley Fischer, Katharine M. O'Connor and Stephen Wu on May 27, 2020
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
If you missed our latest webinar, enjoy the replay below and learn more as we provide highlights on competitor collaborations, avoiding violations in labor markets, provider M&A and partial acquisitions. Competitor Collaborations Antitrust compliance remains an important priority in the US. While companies have been engaged in finding creative solutions to COVID-19 challenges and regulators...
Continue Reading
Third Circuit: “Rigorous Analysis” Required for Class Certification in Antitrust Cases
By Lisa P. Rumin, Nicole Castle and Stephen Wu on May 21, 2020
Posted In Private Litigation
The US Court of Appeals for the Third Circuit recently concluded in In re Lamictal Direct Purchaser Antitrust Litigation that a district court’s reliance on average prices to determine class-wide impact was insufficient. Instead, courts must conduct a rigorous analysis of the facts, evidence and expert testimony at the class certification stage of litigation. Access Full Article
Continue Reading
FTC and DOJ Issue Joint Antitrust Statement Regarding COVID-19 and Competition in Labor Markets
By Ashley Fischer and Stephen Wu on Apr 14, 2020
Posted In Healthcare Antitrust
The COVID-19 pandemic has placed additional stressors on labor markets, particularly for healthcare workers and essential employees. While recognizing that employers, recruiters and staffing agencies may need—and be allowed to—cooperate in unprecedented ways to address current needs, on April 13, 2020, the US Department of Justice and US Federal Trade Commission issued a joint statement...
Continue Reading
Clean Hands Can Stop More than COVID-19: Antitrust Risks in Times of Supply and Demand Shocks
By Ashley Fischer, Joshua W. Eastby and Stephen Wu on Mar 17, 2020
Posted In Cartel Enforcement, DOJ Developments
The potential for government investigation increases during periods of rapid and extreme movement in price. The US Department of Justice (DOJ) recently reiterated its focus on prosecuting violations of antitrust laws, especially in areas affected by the coronavirus outbreak. On March 9, 2020, the DOJ announced that individuals or companies engaging in price fixing, bid-rigging,...
Continue Reading
Procurement Collusion Strike Force’s Focus on Detection Yielding New Investigations
By Gregory E. Heltzer, James W. Kim and Stephen Wu on Mar 10, 2020
Posted In Cartel Enforcement, DOJ Developments
On March 3, 2020, the American Bar Association (ABA) hosted a Q&A with two members of the Procurement Collusion Strike Force (PCSF)—Mark Grundvig, the Assistant Chief of the DOJ Antitrust Division’s Criminal II section, and Marcus Mills, Special Agent, Major Fraud Investigations Division, USPS Office of Inspector General. During the course of the Q&A, Mr....
Continue Reading
Close Scrutiny for Class Settlements Where Plaintiff Attorneys Take Lion’s Share
By Nicole Castle, Michelle Lowery, Matt Evola, Stephen Wu and McDermott Will & Emery on Jan 27, 2020
Posted In Cartel Enforcement, Private Litigation
Two recent US antitrust class action settlements drew additional scrutiny from federal judges, showing that the allocation of settlement funds between a proposed class and their attorneys will be carefully reviewed for fairness to class members.
Continue Reading
